Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
According to Reuters, Bank of America Corporation ( BAC - Analyst Report ) is contemplating the sale of mortgage servicing rights (MSRs) worth $300 billion. This step will be taken by BofA in order to scale down its non-core operations and further strengthen the balance sheet.
Among the companies that are in talks to buy MSRs from BofA (in full or part) include Ocwen Financial Corp. ( OCN - Analyst Report ) , Walter Investment Management Corp. ( WAC - Snapshot Report ) and Nationstar Mortgage Holdings Inc. ( NSM - Snapshot Report ) . The deal is expected to be announced in the next few weeks.
MSRs, in general, are becoming burdensome for the banks. Stringent capital regulations and increasing balance sheet risk have made these an expensive business. Hence, the banks are trying to offload these to specialized mortgage-servicing companies that include three of the abovementioned firms.
In the last couple of years, major banks like Morgan Stanley ( MS - Analyst Report ) and Goldman Sachs Group Inc ( GS - Analyst Report ) have sold their respective mortgage servicing subsidiaries to Ocwen. Last year, Ocwen, in partnership with Walter Investment, also won the bid to acquire Residential Capital's (ResCap) MSRs for $3 billion.
Getting back to the original story, BofA’s mortgage servicing expenses has shot up tremendously. In the third quarter, it stood at $3.4 million as the company had to hire employees to work with those customers who are late in loan repayments. As of September 30, 2012, the company serviced loans worth $1.1 trillion, down from $1.4 trillion as of December 31, 2011.
Moreover, in June 2012, BofA announced a deal to sell $10.4 billion worth of MSRs to Nationstar Mortgage Holdings’ wholly owned subsidiary – Nationstar Mortgage LLC. The MSRs comprise of loans in government-sponsored enterprise (GSE) pools.
Escalating servicing costs and strict regulations is expected to force BofA and many other banks to do away with once lucrative MSRs operations. Currently, BofA retains a Zacks #3 Rank, which translates into a short-term Hold rating.
We believe that BofA’s plan to vend off MSRs will be slightly positive for the company. Hence, there a marginal chance for upward estimate revisions. This in turn, could also lead to an improvement in its Zacks Rank.
Read the full reports :
Analyst Report on MS
Snapshot Report on NSM
Analyst Report on OCN
Analyst Report on GS
Analyst Report on BAC
Snapshot Report on WAC